CD274 and neoplasm: Activation of the already existing PD-L1-specific T-cell response through therapeutic vaccination offers an intriguing way to directly target counter-regulatory pathways in the tumor microenvironment and modulate the local immune suppression without inducing unacceptable toxicity.